ClinicalTrials.gg
RecruitingNCT05357846Updated Apr 30, 2026

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

A Phase 3 interventional study of Sintilimab and Preoperative radiotherapy in Squamous Cell Esophageal Carcinoma, Esophageal Cancer and Oesophageal Cancer, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Sun Yat-sen University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
422
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma — 9 open to participants now, 9 under way, 4 of them phase 3. sintilimab · Esophageal Squamous Cell Carcinoma.

Planned enrollment
2nd of 21
422 · median 52
Started
2022
with 2 others
Phase 3
5 of 21
4 open now
Registered
14th of 21
by date
Lead sponsor
2 of 21
Sun Yat-sen University

Among the 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2022, is one of 5 in phase 3, and was the 14th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

9 of the 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

The primary objective is to compare PD-1 inhibitor combined with preoperative chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery, in terms of the overall survival time (OS) in patients with Stage T1-4aN1-3M0 or T3-4aN0M0 squamous cell esophageal carcinoma.

03

Conditions studied

  • Squamous Cell Esophageal Carcinoma
  • Esophageal Cancer
  • Oesophageal Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histologic diagnosis of squamous cell thoracic esophageal carcinoma of Stage T1-4aN1-3M0 or T3-4aN0M0,which is potentially resectable.
  2. Patients must not have received any prior anticancer therapy.
  3. More than 6 months of expected survival.
  4. Age ranges from 18 to 70 years.
  5. Absolute white blood cells count ≥4.0×109/L, neutrophil ≥1.5×109/L, ≥100.0×109/L, ≥90g/L, and normal functions of liver and kidney.
  6. WHO PS score 0-1
  7. Signed document on file.

Exclusion criteria

Exclusion Criteria:

  1. Patients have received any prior anticancer therapy.
  2. Patients are diagnosed or suspected to be allergic to sintilimab,toxal or cisplatin.
  3. Patients with concomitant hemorrhagic disease.
  4. Patients who cannot tolerate surgery.
  5. Pregnant or breast feeding.
  6. Patients without because of psychological, family, social or any other factors.
  7. Patients with concomitant peripheral neuropathy, whose CTC status is 2 or even more.
  8. Patients with malignant tumors other than esophageal cancer,except for non-melanoma skin cancer, in situ cervical cancer, or cured early prostate cancer.
  9. Patients with history of diabetes over 10 years and unsatisfactory glycemic control.
  10. Patients with severe heart,lung,liver,renal dysfunction, hematopoietic system diseases, immune system diseases, cachexia or other diseases that lead to intolerance of chemoradiotherapy or surgery.
  11. Patients with history of diseases, immunodeficiency, or organ and bone marrow transplantation.
  12. Patients with history of interstitial lung disease or noninfectious pneumonia.
  13. Patients with active pulmonary tuberculosis infection, or a history of active pulmonary tuberculosis infection within one year before enrollment, or a history of active pulmonary tuberculosis infection more than one year ago without regular treatment.
  14. Patients with active ( HBV DNA ≥ 2000 IU / mL or 104 copies / mL ) or ( HCV antibody positive ).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
422 participants (estimated)

Study arms

  • Experimental
    NCRT+IO group

    • NCRT+IO group consists of the PD-1 inhibitor combined with concurrent chemoradiotherapy prior to surgery. The patient will receive 4 weeks of radiation therapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks.PD-1 inhibitor is given by intravenous infusion on days 1 and 22. Chemotherapy is given by intravenous infusion on days 1, 8, 15, and 22. Interventions: * Radiation: (40 or 45 Gy/20 fractions) * Drug: Sintilimab * Drug: Paclitaxel * Drug: Cisplatin

    Drug: Sintilimab · Radiation: Preoperative radiotherapy · Drug: Paclitaxel · Drug: Cisplatin · Procedure: esophagectomy

  • Active comparator
    NCRT group

    • NCRT group consists of the concurrent chemoradiotherapy prior to surgery. The patient will receive 4 weeks of radiation therapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Chemotherapy is given by intravenous infusion on days 1, 8, 15, and 22. Interventions: * Radiation: (40 or 45 Gy/20 fractions) * Drug: Paclitaxel * Drug: Cisplatin

    Radiation: Preoperative radiotherapy · Drug: Paclitaxel · Drug: Cisplatin · Procedure: esophagectomy

Interventions

  • Sintilimab 200mg, IV (in the vein) on day 1 and day 22

  • RadiationPreoperative radiotherapy

    External radiation with a total dose of 40.0 or 45.0 Gy is given in 20 fractions,5 fractions a week.

  • 50mg/m2, IV (in the vein) on day 1,day 8,day 15 and day 22

    Also known as: Taxol

  • 25mg/m2,IV DRIP on day 1,day 8,day 15 and day 22

    Also known as: DDP

  • Procedureesophagectomy

    McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 6-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.

06

What researchers measure

Primary outcomes

  1. Overall survival

    Overall survival will be calculated from the date of randomization and an event registered on the date of death from any cause. Patients lost to follow up, or those with no death recorded on the day the database is frozen, will be censored on the date of last follow up.

    Time frame: At end of enrollment- up to 5 years in follow up

Secondary outcomes

  1. Progression free survival

    Progression free survival is defined as the time from randomization until objective tumor progression or death.

    Time frame: At end of enrollment- up to 5 years in follow up

  2. Pathologic complete response rate

    No malignant tumor cells were detected in the removed specimens including primary tumor and lymph nodes

    Time frame: Two weeks after surgery

  3. R0 resection rate

    The percentage of patients who undergo complete resection

    Time frame: Two weeks after surgery

  4. Incidence of perioperative complications

    Incidence of complications

    Time frame: Ninety days after surgery

  5. Perioperative mortality

    Incidence of death postoperatively

    Time frame: Ninety after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Jan 2031, 98 months after the start.

Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's planned 98 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2022
First posted
May 3, 2022
StartActual
Nov 1, 2022
Primary completionEst.
Jan 1, 2031
CompletionEst.
Jan 31, 2031
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05357846
Collaborators
Affiliated Cancer Hospital of Shantou University Medical College
Responsible party
Yang Hong (Prof., Sun Yat-sen University) — Principal investigator
First posted
May 3, 2022
Start date
Nov 1, 2022
Primary completion
Jan 1, 2031 (estimated)
Completion
Jan 31, 2031 (estimated)
Last update
Apr 30, 2026

Study contacts

HONG YANG, M.D. Ph.D.
Contact
yanghong@sysucc.org.cn
8602087343 ext. 8602087343
HONG YANG
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion